PROF | Profound Medical Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.05 - 9.16
52 Week Range	7.11 - 11.69
Beta	0.65
Implied Volatility	111.88%
IV Rank	47.77%
Day's Volume	267,611
Average Volume	45,079
Shares Outstanding	24,481,800
Market Cap	200,750,760
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2019-10-29

Valuation
Profitability
Growth
Health
P/E Ratio	-6.72
Forward P/E Ratio	N/A
EPS	-1.22
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	131
Country	Canada
Website	PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

PROF's peers: ICAD, SIBN, SGHT, NVRO, FNA, LUNG, IRMD, OFIX, NPCE, ITGR, OSA, LIVN, ELMD, KIDS, SRDX, CVRX, AORT, HSKA, QIPT, RBOT, VMD

*Chart delayed

Analyzing fundamentals for PROF we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see PROF Fundamentals page.

Watching at PROF technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on PROF Technicals page.